EGFR inhibitors mainly target activating EGFR mutations in non-small-cell lung cancer (NSCLC), and EGFR expression and EGFR mutations have been investigated as potential predictors of responsiveness to EGFR tyrosine kinase inhibitors in NSCLC [47]. Here, EGFR is linked to non-small cell lung carcinoma.